2024 annual financial data
Iovance Biotherapeutics 2024 Operating margin
Direct answer
Operating margin was -240.92%.
Operating income was -395,278,000 USD and net income was -372,177,000 USD.
Operating cash flow was -352,977,000 USD.
Get free Iovance Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 164,070,000 USD
- Operating income
- -395,278,000 USD
- Net income
- -372,177,000 USD
- Operating cash flow
- -352,977,000 USD